title: Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology.
authors: Yvoir, Belgium; H. P. Krayenbühl, Zürich, Switzerland, M. Krzeminska-Pakula, Lodz, Poland; M. Samama, Paris, France.
authors: C
authors: C
authors: Gohlke-Bärwolf
authors: J
authors: J
authors: Acar
authors: C
authors: C
authors: Oakley
authors: E
authors: E
authors: Butchart
authors: D
authors: D
authors: Burckhart
authors: E
authors: E
authors: Bodnar
authors: R
authors: R
authors: Hall
authors: J P
authors: JP
authors: Delahaye
authors: D
authors: D
authors: Horstkotte
authors: R
authors: R
authors: Krémer
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006349:Heart Valve Diseases / Q000097:blood / Q000150:complications*; D006350:Heart Valve Prosthesis; D006801:Humans; D007231:Infant, Newborn; D011183:Postoperative Complications / Q000097:blood / Q000517:prevention & control*; D011247:Pregnancy; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants